Literature DB >> 24488579

Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs.

Javier Pascual-Ramírez1, Susana Sánchez García, Francisco González Ruiz de la Herrán, Pedro Villarejo Campos, Carlos López de la Manzanara Cano, Javier Haya Palazuelo, David Padilla Valverde, Jesús Martín Fernández.   

Abstract

OBJECTIVE: To present physiologic intraoperative data and immediate postoperative outcomes of patients diagnosed with epithelial ovarian cancer submitted to cytoreductive surgery and hyperthermic peritoneal intraoperative chemotherapy (HIPEC) with a closed-circuit, turbulent-flow system.
MATERIALS AND METHODS: A closed-circuit system with CO2 turbulent flow was used for paclitaxel HIPEC during 60 min for patients diagnosed with stage II or higher and recurrent epithelial ovarian cancer. Perioperative hemodynamic and metabolic statuses were followed, as well as physiologic recovery during the first 12 postoperative hours. A non-parametric statistical analysis was performed.
RESULTS: At the end of the hyperthermia phase, temperature was 37.7 ± 0.6 °C, heart rate 88 ± 19 bpm, cardiac index 2.8 ± 0.5 L min(-1) m(-2), stroke volume variation 14.6 ± 3.6 % and extravascular lung water 8.7 ± 1.9 mL kg(-1). No hyperdynamic status was recorded. The length of stay in the ICU was 2½ days, and 12.7 ± 7 days in hospital. Average postoperative intubation time was 11.7 ± 17.4 h. At the ICU admission time, glucose, lactic acid and hemoglobin were the only values out of range, but close to normal. SOFA median was 3 at admission and 0 the following day.
CONCLUSION: A turbulent-flow, closed-circuit use for hyperthermic peritoneal intraoperative chemotherapy resulted in no hyperdynamic response or coagulopathy, had good tolerance and promoted early physiologic recovery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24488579     DOI: 10.1007/s00404-014-3153-4

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  5 in total

Review 1.  A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement.

Authors:  Maneesh K Beeharry; Wen-Tao Liu; Xue-Xin Yao; Min Yan; Zheng-Gang Zhu
Journal:  Transl Gastroenterol Hepatol       Date:  2016-10-20

Review 2.  The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer.

Authors:  W J van Driel; C A R Lok; V Verwaal; G S Sonke
Journal:  Curr Treat Options Oncol       Date:  2015-04

3.  Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41.

Authors:  David Padilla-Valverde; Esther García-Santos; Susana Sanchez; Carmen Manzanares; Marta Rodriguez; Lucia González; Alfonso Ambrós; Juana M Cano; Leticia Serrano; Raquel Bodoque; Teresa Vergara; Jesus Martin
Journal:  J Gastrointest Oncol       Date:  2021-04

4.  Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC.

Authors:  E Halkia; A Tsochrinis; D T Vassiliadou; A Pavlakou; A Vaxevanidou; A Datsis; E Efstathiou; J Spiliotis
Journal:  Int J Surg Oncol       Date:  2015-02-15

5.  Are there intra-operative hemodynamic differences between the Coliseum and closed HIPEC techniques in the treatment of peritoneal metastasis? A retrospective cohort study.

Authors:  Cristina Rodríguez Silva; Francisco Javier Moreno Ruiz; Inmaculada Bellido Estévez; Joaquin Carrasco Campos; Alberto Titos García; Manuel Ruiz López; Ivan González Poveda; Jose Antonio Toval Mata; Santiago Mera Velasco; Julio Santoyo Santoyo
Journal:  World J Surg Oncol       Date:  2017-02-21       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.